Page 67 - 2020_08-Haematologica-web

European Consensus for treatment of hemophilia
tion factor concentrates. Haemophilia.
2017;23(3):370-375.
5. Council of Europe, Committee of Ministers,
Resolution CM/Res(2017)43 on principles concerning haemophilia therapies (replacing Resolution CM/Res(2015)3).
6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treat- ment to prevent joint disease in boys with severe haemophilia. N Engl J Med. 2007;357(6):535-544.
7. Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary state- ment. Haemophilia. 2003;9(Suppl 1):1-4.
8. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermedi- ate-dose to a high-dose regimen. Haemophilia. 2002;8 (6):753-760.
9. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treat- ments, and its complications. Lancet. 2016;388(10040):187-197.
10. Berntorp E, Andersson NG. Prophylaxis for hemophilia in the Era of extended Half-Life Factor VIII/Factor IX Products. Semin Thromb Hemost. 2016;42(5):518-525.
11. Peters R, Harris T. Advances and innova- tions in haemophilia treatment. Nat Rev Drug Discov. 2018;17(7):493-508.
12. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377 (9):809-818.
13. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
14. Stephensen D, de Kleijn P, Matlary RED, et
al. EAHAD Physiotherapists Committee. Scope of practice of haemophilia physio- therapists: A European survey. Haemophilia. 2019;25(3):514-520.
15. Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl. 4):131-135. 16. Hazendonk HCAM, van Moort I, Mathôt
RAA, et al. Setting the stage for individual- ized therapy in hemophilia: What role can pharmacokinetics play? Blood Rev. 2018;32 (4):265-271.
17. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to pre- dicted factor VIII levels in patients receiv- ing prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-420.
18. Kitchen S, Tiefenbacher S, Gosselin R. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies. Semin Thromb Haemost. 2017:43(3):331-337.
19. Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F. Advances in the treatment of hemophilia: Implications for laboratory test- ing. Clin Chem. 2019;65(2):254-262.
20. Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measure- ments of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16(7):1383-1390.
21. Teichman J, Chaudhry HR, Sholzberg M. Novel assays in the coagulation laboratory: a clinical and laboratory perspective. Transfus Apher Sci. 2018:57(4):480-484.
22. Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost.
2019;119(9):1384-1393.
23. Collins PW, Liesner R, Makris M, et al.
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018;24(3):344-347.
24. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/ 144533/2009 rev. 2
25. Keipert C, Jonker CJ, van den Berg HM, Hilger A. Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from dif- ferent data sources. Haemophilia. 2018;24 (3):420-428.
26. Report on Haemophilia Registries: Workshop 8 June 2018. EMA/487643/2018. https://www.ema.europa.eu/en/docu- ments/report/report-haemophilia-registries- workshop_en.pdf
27. Peyvandi F, Makris M, Collins P, et al. Minimal dataset for post-registration sur- veillance of new drugs in hemophilia: com- munication from the SSC of the ISTH. J Thromb Haemost. 2017;15(9):1878-1881.
28. Keipert C, Hesse J, Haschberger B, et al. The growing number of hemophilia registries: Quantity versus quality. Clin Pharmacol Ther. 2015;97(5):492-501.
29. Berger KC, Feldman BM, Wasserman J, et al. Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed. Haematologica. 2016;101(3):266-268.
30. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105 (3):545-553.
haematologica | 2020; 105(8)
2043